



Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in an STI population; performances of Presto, Lightmix Kit 480 HT CT/NG, and COBAS Amplicor with urine specimens and urethral/cervicovaginal samples

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003607
Article Type:	Research
Date Submitted by the Author:	19-Sep-2013
Complete List of Authors:	Schuurs, Theo; Izore, Centre for Infectious Diseases Friesland, Verweij, Stephan; VU University Medical Center, Laboratory of Immunogenetics, dept. Medical Microbiology and Infection Control Weel, Jan; Izore, Centre for Infectious Diseases Friesland, Ouburg, Sander; VU University Medical Center, Laboratory of Immunogenetics, dept. Medical Microbiology and Infection Control Morre, S; VU University Medical Center, Laboratory of Immunogenetics, dept. Medical Microbiology and Infection Control; University of Maastricht, 3Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institute GROW, Faculty of Health, Medicine & Life Sciences
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Diagnostics
Keywords:	INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, MICROBIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 1 **Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in an STI**
4
5 2 **population; performances of Presto, Lightmix Kit 480 HT CT/NG, and COBAS**
6
7 3 **Amplicor with urine specimens and urethral/cervicovaginal samples**
8
9
10 4

11 T.A. Schuurs^{1#}, S.P. Verweij^{2#}, J.F.L. Weel¹, S. Ouburg², S.A. Morré^{2,3+}
12
13
14

15
16 7 ¹Izore, Centre for Infectious Diseases Friesland, Leeuwarden, The Netherlands
17

18 8 ²Laboratory of Immunogenetics, Department of Medical Microbiology and Infection
19 Control, VU University Medical Center, Amsterdam, The Netherlands
20
21

22 9
23 10 ³Institute of Public Health Genomics, Department of Genetics and Cell Biology,
24 Research Institute GROW, Faculty of Health, Medicine & Life Sciences, University of
25 Maastricht, Maastricht, The Netherlands
26
27
28
29

30
31
32 14 *Address of correspondence: VU University Medical Center, Department of Medical
33 Microbiology and Infection Control, Laboratory of Immunogenetics, Location: MF
34 B330, To: S.A. Morré, Head of, De Boelelaan 1117, 1081 HV, Amsterdam, The
35 Netherlands
36
37
38
39

40 18 E-mail: samorretravel@yahoo.co.uk, Phone: +31-20-44-49375, Fax: +31-20-44-
41 48418
42
43
44

45 20 #These authors contributed equally to the manuscript
46
47
48

49
50 22 Abstract no. of words: 218 (max. 300)

51 23 Body text no. of words: 977 (max. 1000)

52 24 References: 11

53 25 Tables/figures: 2
54
55
56
57
58
59
60

1 Article summary

3 Article focus

- 4 • To evaluate performances of three commercially available nucleic acid
5 amplification tests (NAAT) in the detection of *Chlamydia trachomatis* and
6 *Neisseria gonorrhoeae*: Presto, Lightmix Kit 480 HT CT/NG, and COBAS
7 Amplicor.

9 Key messages

- 10 • Prevalence of *C. trachomatis* and *N. gonorrhoeae* is stable or slightly
11 increasing in the Netherlands. Well functioning diagnostic tools are essential
12 within the healthcare.
- 13 • All three NAATs evaluated in this study are highly sensitive and specific for
14 detection of *C. trachomatis*, with best performance for Presto.

16 Strengths and limitations

- 17 • Although our sample size was quite large, our study had a limited number of
18 *N. gonorrhoeae* positive samples, so no sensitivities, specificities, positive
19 predictive values and negative predicting values were calculated for *N.*
20 *gonorrhoeae*.

1
2
3 1 **Abstract**

4
5 2

6
7 3 **Objectives**

8
9 4 This study assessed the performances of Presto CT/NG assay, Lightmix Kit 480 HT
10
11 5 CT/NG, and the COBAS Amplicor for *Chlamydia trachomatis* and *Neisseria*
12
13 6 *gonorrhoeae* detection.
14
15

16
17 7
18 8 **Design**

19
20 9 It is a prospective study design.
21
22

23
24 10
25 11 **Setting**

26
27 12 IZore, Centre for Diagnosing Infectious Diseases in Friesland, the Netherlands, tested
28
29 13 samples sent from regional STI outpatient clinics and regional hospital from the
30
31 14 province Friesland, the Netherlands.
32
33

34
35 15
36 16 **Participants**

37
38 17 Samples were collected from 292 men and 835 women. These samples included 560
39
40 18 urine samples and 567 urethral/cervicovaginal samples.
41
42

43
44 19
45 20 **Primary and secondary outcome measures**

46
47 21 Primary outcome measure is *C. trachomatis* infection. No secondary outcome
48
49 22 measures are available.
50
51

52
53 23
54 24 **Results**
55
56
57
58
59
60

1 The sensitivity, specificity, positive predicative value (PPV), and negative predictive
2 value (NPV) for *C. trachomatis* detection in urine samples using Presto were 100,0%,
3 99,8%, 98,1%, 100,0%, respectively; for Lightmix Kit 480 HT CT/NG: 94,2%, 99,8%,
4 96,1%, 99,4%, respectively; for COBAS Amplicor: 92,3%, 99,6%, 96,0%, 99,2%,
5 respectively. The sensitivity, specificity, PPV, and NPV for *C. trachomatis* detection in
6 urethral/cervicovaginal swabs using Presto and COBAS Amplicor were 100,0%,
7 99,8%, 97,7%, 100,0%, respectively; for Lightmix Kit 480 HT CT/NG: 100,0%, 99,6%,
8 97,7%, 100,0%, respectively. Calculations for *N. gonorrhoeae* could not be made due
9 to a low prevalence.

10

11 **Conclusions**

12 All three assays had a high sensitivity, specificity, PPV, and NPV for *C. trachomatis*,
13 with best performance for the Presto CT/NG assay.

1 Introduction

Urogenital *Chlamydia trachomatis* and *Neisseria gonorrhoeae* are the most prevalent bacterial sexually transmitted infections (STI) in the Netherlands [1]. Both infections are associated with severe sequelae including pelvic inflammatory disease, tubal scarring, and tubal infertility [2;3]. In Western society, highly sensitive and specific DNA or RNA amplification tests to detect *C. trachomatis* and *N. gonorrhoeae* are commercially available, and have increased detection rates as compared to conventional techniques including culture [4-6]. A variety of clinical specimens, *i.e.* urine specimens and cervicovaginal, anorectal, or oropharyngeal swabs, can be used for STI detection, and cost-saving test strategies have been described [2;7]. Until recently, COBAS Amplicor (Roche, CA, USA) was the most widely used system for *C. trachomatis* and *N. gonorrhoeae* detection in the Netherlands. Newly developed dual detection systems for *C. trachomatis* and *N. gonorrhoeae* are implemented in Europe in the last two years including the Presto CT/NG assay (Goffin Molecular Technologies, Houten, The Netherlands) and the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany).

The aim of this prospective study was to compare the performances of the Presto CT/NG assay, the Lightmix Kit 480 HT CT/NG, and COBAS Amplicor in urine specimens and urethral/cervicovaginal samples for the detection of *C. trachomatis* and *N. gonorrhoeae* in patients visiting general practitioners, gynaecologists and dermato-venereologists for complaints most commonly generated by an STI.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 **Material and Methods**

4 **Clinical specimens**

5 Urine specimens (n = 560, 238 men and 322 women) and urethral/cervicovaginal
6 swabs (n = 567, 54 men and 513 women) were obtained from 292 men and 835
7 women. Samples were sent to Izore, Centre for Diagnosing Infectious Diseases in
8 Friesland, the Netherlands, for routine STI testing by regional hospitals and general
9 practitioners. Samples were obtained in the period from March - May 2010.

11 **DNA isolation**

12 DNA was isolated with MP96 (Roche) according to manufacturer's protocol. DNA
13 extraction from the urine samples and swabs for the COBAS Amplicor was performed
14 on the COBAS platform.

16 ***C. trachomatis* and *N. gonorrhoeae* testing**

17 *C. trachomatis* and *N. gonorrhoeae* detection was performed with the Presto CT/NG
18 assay (Goffin Molecular Technologies, Houten, The Netherlands), the Lightmix Kit
19 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany), and COBAS Amplicor (Roche, CA,
20 USA). All tests were performed according to the protocols provided by the respective
21 manufacturers. Due to cross-reactivity with other *Neisseria spp.*, COBAS Amplicor-
22 positive-results were confirmed with *opa* PCR. Two qualified technicians performed
23 the tests and were blinded for the results.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

2 Discrepancy analysis and statistical analysis

3 Samples identified as *C. trachomatis* positive or *C. trachomatis* negative with Presto,
4 TIB MOLBIOL, and COBAS Amplicor were defined as true positives and true
5 negatives, respectively using an alloyed gold standard: If two out of three tests were
6 positive, the sample was considered positive. If only one test was positive, the
7 sample was considered negative. The same algorithm was used for *N. gonorrhoeae*.
8 To calculate the sensitivity, specificity, positive predictive value (PPV), and the
9 negative predictive value (NPV), we used the alloyed gold standard as reference [8].
10 95% Wilson Binomial Confidence Intervals were calculated for the sensitivities,
11 specificities, PPVs, and NPVs [9].

1 Results

2
3 The overall prevalence for *C. trachomatis* and *N. gonorrhoeae* in this study was 8.1-
4 8.5% and 0.8-0.9% respectively. Since the number of *N. gonorrhoeae* positive
5 samples was very limited, we could not reliably calculate sensitivity, specificity, PPV,
6 and NPV.

7
8 Using the Presto assay *C. trachomatis* DNA was detected in 53 out of 560 urine
9 specimens and in 43 out of 567 urethral/cervicovaginal specimens, while the Lightmix
10 Kit 480 HT CT/NG and COBAS Amplicor resulted in 51 and 40, and 50 and 43 *C.*
11 *trachomatis* positives, respectively. The sensitivity, specificity, PPV and NPV for *C.*
12 *trachomatis* are summarized in Table 1.

13
14 For *N. gonorrhoeae*, Presto detected 3 out of 560 urine specimens and 7 out of 567
15 urethral/cervicovaginal specimens. The Lightmix Kit 480 HT CT/NG and COBAS
16 Amplicor (followed by opaA confirmation PCR on *N. gonorrhoeae* positives) detected
17 3 and 7, and 1 and 8 respectively.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1 **Table 1. Sensitivity, specificity, PPV and NPV for the three assays.**

2

Urine <i>C. trachomatis</i>								
	Sensitivity	95% CI	Specificity	95% CI	PPV	95% CI	NPV	95% CI
Presto CT/NG assay	100,0	0,9932 - 1,000	99,8	0,9896 - 0,9996	98,1	0,9660 - 0,9895	100,0	0,9932 - 1,000
Lightmix Kit 480 HT CT/NG	94,2	0,9195 - 0,9585	99,8	0,9896 - 0,9996	96,1	0,9416 - 0,9741	99,4	0,9834 - 0,9978
Cobas Amplicor	92,3	0,8980 - 0,9423	99,6	0,9864 - 0,9988	96,0	0,9404 - 0,9733	99,2	0,9806 - 0,9967

3

Urethral/cervicovaginal <i>C. trachomatis</i>								
	Sensitivity	95% CI	Specificity	95% CI	PPV	95% CI	NPV	95% CI
Presto CT/NG assay	100,0	0,9933 - 1,000	99,8	0,9897 - 0,9996	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000
Lightmix Kit 480 HT CT/NG	100,0	0,9933 - 1,000	99,6	0,9865 - 0,9988	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000
Cobas Amplicor	100,0	0,9933 - 1,000	99,8	0,9897 - 0,9996	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000

1 Discussion

2
3
4
5
6
7 In the Netherlands, the prevalence of STI is stable or slightly increasing [1]. Besides
8 education also accurate diagnostics is essential for prevention of further spreading of
9 STI in the healthy population. Therefore diagnostic tests, detecting STI's, should
10 display maximum sensitivity whereas false-positives have to be precluded at any
11 time.
12

13 We compared the performance of the Presto CT/NG assay (Goffin Molecular
14 Technologies), the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL), and the Cobas
15 AmpliCor (Roche) to an alloyed gold standard, defined as a positive result in at least
16 two out of three tests. The used samples were urine and urogenital swabs. The
17 results show high specificity, sensitivity, PPV, and NPV for all tests, with the Presto
18 CT/NG assay as best overall performance.
19

20 Due to the low prevalence of *N. gonorrhoeae*, we were not able to calculate
21 specificity, sensitivity, PPV, and NPV. The overall prevalence of *N. gonorrhoeae* in
22 this study population was 0.8-0.9%, which is in concordance with a recent report of
23 the National Institute for Public Health and the Environment stating that Friesland
24 province has an *N. gonorrhoeae* prevalence of 1-2% [1]. The prevalence of *C.*
25 *trachomatis* in this study population is slightly lower than the reported annual
26 prevalence: 8.1-8.5% vs. 12-14% [1]. This observed difference may be explained by
27 the fact that the National Institute for Public Health and the Environment includes
28 data from all STI outpatient clinics in the Netherlands, whereas this study uses
29 samples from a single region.
30

1
2
3 1 Performance of the COBAS Amplicor regarding *C. trachomatis* detection in this study
4
5 2 was comparable to its performance in other studies [10;11]. In these other studies,
6
7 3 similar high sensitivities, specificities, PPVs, and NPVs were achieved, as we do in
8
9 4 this study. Due to too small number specificity, sensitivity, PPV and NPV could not be
10
11 5 calculated for *N. gonorrhoeae*.
12
13
14 6

15
16 7 To conclude, we find high specificity, sensitivity, PPV, and NPV for all tests for *C.*
17
18 8 *trachomatis*, with the Presto CT/NG assay having the best overall performance.
19
20
21 9

1 Acknowledgements

2

3 We would like to acknowledge Renske Minnema and Griet Verbeek (Izore, Centre for
4 Infectious Diseases Friesland, Leeuwarden, The Netherlands) for the technical
5 support. Prof.dr. S.A. Morré, employed by the VU University medical center has been
6 involved in the technical development of the PRESTO test (Goffin Molecular
7 Technologies, Houten, The Netherlands) via Microbiome Ltd. a spin-in company of
8 the VU University Medical Center, Amsterdam, The Netherlands.


Reference List

- [1] Trienekens SCM, Koedijk FDH, Van den Broek IVF, Vriend HJ, Op de Coul ELM, Van Veen MG, et al. Sexually transmitted infections, including HIV, in the Netherlands in 2011. National Institute for Public Health and the Environment, Bilthoven, The Netherlands; 2012. Report No.: 201051001.
- [2] Land JA, van Bergen JE, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010 Mar;16(2):189-204.
- [3] Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhoea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhoea. JAMA 1983 Dec 16;250(23):3205-9.
- [4] Goessens WH, Mouton JW, van der Meijden WI, Deelen S, van Rijsoort-Vos TH, Lemmens-den TN, et al. Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol 1997 Oct;35(10):2628-33.
- [5] Quint KD, van Doorn LJ, Kleter B, de Koning MN, van den Munckhof HA, Morré SA, et al. A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identification of Chlamydia trachomatis serovars. J Mol Diagn 2007 Nov;9(5):631-8.

- 1
2
3 1 [6] Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Melby KK, Moi H, et al.
4
5 2 Clinical validation of a real-time polymerase chain reaction detection of
6
7 3 *Neisseria gonorrhoeae* porA pseudogene versus culture techniques. *Sex Transm*
8
9 4 *Dis* 2008 May;35(5):517-20.
- 10
11
12 5 [7] Morre SA, Meijer CJ, Munk C, Kruger-Kjaer S, Winther JF, Jorgensens HO, et
13
14 6 al. Pooling of urine specimens for detection of asymptomatic *Chlamydia*
15
16 7 *trachomatis* infections by PCR in a low-prevalence population: cost-saving
17
18 8 strategy for epidemiological studies and screening programs. *J Clin Microbiol*
19
20 9 2000 Apr;38(4):1679-80.
- 21
22
23 10 [8] Spiegelman D, Schneeweiss S, McDermott A. Measurement error correction for
24
25 11 logistic regression models with an "alloyed gold standard". *Am J Epidemiol* 1997
26
27 12 Jan 15;145(2):184-96.
- 28
29
30 13 [9] Wilson EB. Probable inference, the law of succession, and statistical inference.
31
32 14 *J Am Stat Assoc* 1927;22:209-12.
- 33
34
35 15 [10] Jalal H, Al-Suwaine A, Stephen H, Carne C, Sonnex C. Comparative
36
37 16 performance of the Roche COBAS Amplicor assay and an in-house real-time
38
39 17 PCR assay for diagnosis of *Chlamydia trachomatis* infection. *J Med Microbiol*
40
41 18 2007 Mar;56(Pt 3):320-2.
- 42
43
44 19 [11] Cheng A, Qian Q, Kirby JE. Evaluation of the Abbott RealTime CT/NG assay in
45
46 20 comparison to the Roche Cobas Amplicor CT/NG assay. *J Clin Microbiol* 2011
47
48 21 Apr;49(4):1294-300.
- 49
50
51
52
53
54
55
56
57
58
59
60

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	4
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	5
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	5
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	4
<i>Test methods</i>	7	The reference standard and its rationale.	6
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5, 6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5, 6
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	n/a
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	n/a
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	6
	13	Methods for calculating test reproducibility, if done.	n/a
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	n/a
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	7
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	7
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	n/a
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	n/a
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	n/a
	20	Any adverse events from performing the index tests or the reference standard.	n/a
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	8
	22	How indeterminate results, missing data and outliers of the index tests were handled.	n/a
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	n/a
	24	Estimates of test reproducibility, if done.	n/a
DISCUSSION	25	Discuss the clinical applicability of the study findings.	9



Flow chart of the study
169x148mm (72 x 72 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in an STI population; performances of Presto CT-NG assay, Lightmix Kit 480 HT CT/NG, and COBAS Amplicor with urine specimens and urethral/cervicovaginal samples

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003607.R1
Article Type:	Research
Date Submitted by the Author:	18-Nov-2013
Complete List of Authors:	Schuurs, Theo; Izore, Centre for Infectious Diseases Friesland, Verweij, Stephan; VU University Medical Center, Laboratory of Immunogenetics, dept. Medical Microbiology and Infection Control Weel, Jan; Izore, Centre for Infectious Diseases Friesland, Ouburg, Sander; VU University Medical Center, Laboratory of Immunogenetics, dept. Medical Microbiology and Infection Control Morre, S; VU University Medical Center, Laboratory of Immunogenetics, dept. Medical Microbiology and Infection Control; Univerity of Maastricht, 3Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institute GROW, Faculty of Health, Medicine & Life Sciences
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Diagnostics
Keywords:	INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, MICROBIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 1 **Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in an STI**
4
5 2 **population; performances of Presto CT-NG assay, Lightmix Kit 480 HT CT/NG,**
6
7 3 **and COBAS Amplicor with urine specimens and urethral/cervicovaginal**
8
9 4 **samples**
10

11
12
13
14 6 T.A. Schuurs^{1#}, S.P. Verweij^{2#}, J.F.L. Weel¹, S. Ouburg², S.A. Morré^{2,3+}
15
16
17

18 8 ¹Izore, Centre for Infectious Diseases Friesland, Leeuwarden, The Netherlands
19

20 9 ²Laboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU
21
22 University Medical Center, Amsterdam, The Netherlands
23

24 11 ³Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institute
25
26 GROW, Faculty of Health, Medicine & Life Sciences, University of Maastricht, Maastricht, The
27
28 Netherlands
29

30 14
31
32 15 ⁺Address of correspondence: VU University Medical Center, Department of Medical
33
34 16 Microbiology and Infection Control, Laboratory of Immunogenetics, Location: MF
35
36 17 B330, To: S.A. Morré, Head Lol, De Boelelaan 1117, 1081 HV, Amsterdam, The
37
38 18 Netherlands
39

40
41 19 E-mail: samorretravel@yahoo.co.uk, Phone: +31-20-44-49375, Fax: +31-20-44-
42
43 20 48418
44

45 21 [#]These authors contributed equally to the manuscript
46

47 22 Abstract no. of words: 218 (max. 300)
48

49 23 Body text no. of words: 977 (max. 1000)
50

51 24 References: 11
52

53
54 25 Tables : 1
55

56 26 figures: 1
57
58
59
60

1

2 **Abstract**

3

4 **Objectives**

5 This study assessed the performances of Presto CT-NG assay, Lightmix Kit 480 HT
6 CT/NG, and the COBAS Amplicor for *Chlamydia trachomatis* and *Neisseria*
7 *gonorrhoeae* detection.

8

9 **Design**

10 It is a cross-sectional study design.

11

12 **Setting**

13 IZore, Centre for Diagnosing Infectious Diseases in Friesland, the Netherlands, tested
14 samples sent from regional STI outpatient clinics and regional hospitals from the
15 province Friesland, the Netherlands.

16

17 **Participants**

18 Samples were collected from 292 men and 835 women. These samples included 560
19 urine samples and 567 urethral/cervicovaginal samples.

20

21 **Primary and secondary outcome measures**

22 Primary outcome measure is *C. trachomatis* infection. No secondary outcome
23 measures are available.

24

25 **Results**

26

27

28

29

1 The sensitivity, specificity, positive predicative value (PPV), and negative predictive
2 value (NPV) for *C. trachomatis* detection in urine samples using Presto were 100,0%,
3 99,8%, 98,1%, 100,0%, respectively; for Lightmix Kit 480 HT CT/NG: 94,2%, 99,8%,
4 96,1%, 99,4%, respectively; for COBAS Amplicor: 92,3%, 99,6%, 96,0%, 99,2%,
5 respectively. The sensitivity, specificity, PPV, and NPV for *C. trachomatis* detection in
6 urethral/cervicovaginal swabs using Presto and COBAS Amplicor were 100,0%,
7 99,8%, 97,7%, 100,0%, respectively; for Lightmix Kit 480 HT CT/NG: 100,0%, 99,6%,
8 97,7%, 100,0%, respectively. Calculations for *N. gonorrhoeae* could not be made due
9 to a low prevalence.

11 Conclusions

12 All three assays had a high sensitivity, specificity, PPV, and NPV for *C. trachomatis*,
13 with best performance for the Presto CT-NG assay.

15 Article summary

17 Article focus

- 18 • To evaluate performances of three commercially available nucleic acid
19 amplification tests (NAAT) in the detection of *Chlamydia trachomatis* and
20 *Neisseria gonorrhoeae*: Presto CT-NG assay, Lightmix Kit 480 HT CT/NG, and
21 COBAS Amplicor.

23 Key messages

- 1
2
3 1 • Prevalence of *C. trachomatis* and *N. gonorrhoeae* is stable or slightly
4
5 2 increasing in the Netherlands. Well functioning diagnostic tools are essential
6
7 3 within the healthcare.
8
9
10 4 • All three NAATs evaluated in this study are highly sensitive and specific for
11
12 5 detection of *C. trachomatis*, with best performance for the Presto CT-NG
13
14 6 assay.
15
16
17
18
19

8 Strengths and limitations

- 20
21 9 • Although our sample size was quite large, our study had a limited number of
22
23 10 *N. gonorrhoeae* positive samples, so no sensitivities, specificities, positive
24
25 11 predictive values and negative predicting values were calculated.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

Urogenital *Chlamydia trachomatis* and *Neisseria gonorrhoeae* are the most prevalent bacterial sexually transmitted infections (STI) in the Netherlands [1]. In women, both infections are associated with severe sequelae including pelvic inflammatory disease, tubal scarring, and tubal infertility [2;3]. In Western society, highly sensitive and specific DNA or RNA amplification tests to detect *C. trachomatis* and *N. gonorrhoeae* are commercially available, and have increased detection rates as compared to conventional techniques including culture [4-6]. A variety of clinical specimens, *i.e.* urine specimens and cervicovaginal, anorectal, or oropharyngeal swabs, can be used for STI detection, and cost-saving test strategies have been described [2;7]. Until recently, COBAS Amplicor (Roche, CA, USA) was the most widely used system for *C. trachomatis* and *N. gonorrhoeae* detection in the Netherlands. Newly developed dual detection systems for *C. trachomatis* and *N. gonorrhoeae* are implemented in Europe in the last two years including the Presto CT-NG assay (Goffin Molecular Technologies, Houten, The Netherlands) and the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany).

The aim of this prospective study was to compare the performances of the Presto CT-NG assay, the Lightmix Kit 480 HT CT/NG, and COBAS Amplicor in urine specimens and urethral/cervicovaginal samples for the detection of *C. trachomatis* and *N. gonorrhoeae* in patients visiting general practitioners, gynaecologists and dermato-venereologists for complaints most commonly generated by an STI.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Material and Methods

Clinical specimens

Urine specimens (n = 560, 238 men and 322 women) and urethral/cervicovaginal swabs (n = 567, 54 men and 513 women) were obtained from 292 men and 835 women. Urethral samples were obtained from men only. Samples were sent to Izore, Centre for Diagnosing Infectious Diseases in Friesland, the Netherlands, for routine STI testing by regional hospitals and general practitioners. Samples were obtained in the period from March - May 2010.

DNA isolation

DNA was isolated with MP96 (Roche) according to manufacturer's protocol. DNA extraction from the urine samples and swabs for the COBAS Amplicor was performed on the COBAS platform.

C. trachomatis and *N. gonorrhoeae* testing

C. trachomatis and *N. gonorrhoeae* detection was performed with the Presto CT-NG assay (Goffin Molecular Technologies, Houten, The Netherlands), the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany), and COBAS Amplicor (Roche, CA, USA). All tests were performed according to the protocols provided by the respective manufacturers. Due to cross-reactivity with other *Neisseria spp.*, COBAS Amplicor-positive-results were confirmed with *opa* PCR. Two qualified technicians performed the tests and were blinded for the results.

1

2 Discrepancy analysis and statistical analysis

3 Samples identified as *C. trachomatis* positive or *C. trachomatis* negative with Presto
4 CT-NG assay, Lightmix Kit 480 HT CT/NG, and COBAS Amplicor were defined as
5 true positives and true negatives, respectively using an alloyed gold standard: If two
6 out of three tests were positive, the sample was considered positive. If only one test
7 was positive, the sample was considered negative. The same algorithm was used for
8 *N. gonorrhoeae*.

9 To calculate the sensitivity, specificity, positive predictive value (PPV), and the
10 negative predictive value (NPV), we used the alloyed gold standard as reference [8].
11 95% Wilson Binomial Confidence Intervals were calculated for the sensitivities,
12 specificities, PPVs, and NPVs [9].

1 Results

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 The overall prevalence for *C. trachomatis* and *N. gonorrhoeae* in this study was 8.1-
2 8.5% and 0.8-0.9% respectively. Since the number of *N. gonorrhoeae* positive
3 samples was very limited, we could not reliably calculate sensitivity, specificity, PPV,
4 and NPV.
5
6
7

8 Using the Presto CT-NG assay *C. trachomatis* DNA was detected in 53 out of 560
9 urine specimens and in 43 out of 567 urethral/cervicovaginal specimens, while the
10 Lightmix Kit 480 HT CT/NG and COBAS Amplicor resulted in 51 and 40, and 50 and
11 43 *C. trachomatis* positives, respectively. The sensitivity, specificity, PPV and NPV
12 for *C. trachomatis* are summarized in Table 1.
13

14 For *N. gonorrhoeae*, Presto CT-NG assay detected 3 out of 560 urine specimens and
15 7 out of 567 urethral/cervicovaginal specimens. The Lightmix Kit 480 HT CT/NG and
16 COBAS Amplicor (followed by opaA confirmation PCR on *N. gonorrhoeae* positives)
17 detected 3 and 7, and 1 and 8 respectively.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1 **Table 1. Sensitivity, specificity, PPV and NPV for the three assays for *C. trachomatis* detection.**

2

Urine <i>C. trachomatis</i>								
	Sensitivity	95% CI	Specificity	95% CI	PPV	95% CI	NPV	95% CI
Presto CT-NG assay	100,0	0,9932 - 1,000	99,8	0,9896 - 0,9996	98,1	0,9660 - 0,9895	100,0	0,9932 - 1,000
Lightmix Kit 480 HT CT/NG	94,2	0,9195 - 0,9585	99,8	0,9896 - 0,9996	96,1	0,9416 - 0,9741	99,4	0,9834 - 0,9978
Cobas Amplicor	92,3	0,8980 - 0,9423	99,6	0,9864 - 0,9988	96,0	0,9404 - 0,9733	99,2	0,9806 - 0,9967

3

Urethral/cervicovaginal <i>C. trachomatis</i>								
	Sensitivity	95% CI	Specificity	95% CI	PPV	95% CI	NPV	95% CI
Presto CT-NG assay	100,0	0,9933 - 1,000	99,8	0,9897 - 0,9996	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000
Lightmix Kit 480 HT CT/NG	100,0	0,9933 - 1,000	99,6	0,9865 - 0,9988	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000
Cobas Amplicor	100,0	0,9933 - 1,000	99,8	0,9897 - 0,9996	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000

1 Discussion

2
3 In the Netherlands, the prevalence of STI is stable or slightly increasing [1]. Besides
4 education also accurate diagnostics is essential for prevention of further spreading of
5 STI in the healthy population. Therefore diagnostic tests, detecting STI's, should
6 display maximum sensitivity whereas false-positives have to be precluded at any
7 time.

8 We compared the performance of the Presto CT-NG assay (Goffin Molecular
9 Technologies), the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL), and the Cobas
10 AmpliCor (Roche) to an alloyed gold standard, defined as a positive result in at least
11 two out of three tests. The used samples were urine and urogenital swabs. The
12 results show high specificity, sensitivity, PPV, and NPV for all tests, with the Presto
13 CT-NG assay as best overall performance for *C. trachomatis*.

14
15 Due to the low prevalence of *N. gonorrhoeae*, we were not able to calculate
16 specificity, sensitivity, PPV, and NPV. Presto CT-NG assay and Lightmix Kit 480 HT
17 CT/NG detected *N. gonorrhoeae* equally, but for a definitive validation more samples
18 are needed. The overall prevalence of *N. gonorrhoeae* in this study population was
19 0.8-0.9%, which is in concordance with a recent report of the National Institute for
20 Public Health and the Environment stating that Friesland province has an *N.*
21 *gonorrhoeae* prevalence of 1-2% [1]. The prevalence of *C. trachomatis* in this study
22 population is slightly lower than the reported annual prevalence: 8.1-8.5% vs. 12-
23 14% [1]. This observed difference may be explained by the fact that the National
24 Institute for Public Health and the Environment includes data from all STI outpatient
25 clinics in the Netherlands, whereas this study uses samples from a single region.

1

2
3
4
5 Performance of the COBAS Amplicor regarding *C. trachomatis* detection in this study
6
7 was comparable to its performance in other studies [10;11]. In these other studies,
8
9 similar high sensitivities, specificities, PPVs, and NPVs were achieved, as we found
10
11 in this study.
12

6

7 To conclude, we find high specificity, sensitivity, PPV, and NPV for all tests for *C.*
8 *trachomatis*, with the Presto CT-NG assay having the best overall performance.
9

9

Acknowledgements

We would like to acknowledge Renske Minnema and Griet Verbeek (Izore, Centre for Infectious Diseases Friesland, Leeuwarden, The Netherlands) for the technical support. Prof.dr. S.A. Morré, employed by the VU University medical center has been involved in the technical development of the Presto CT-NG assay (Goffin Molecular Technologies, Houten, The Netherlands) via Microbiome Ltd., a spin-in company of the VU University medical center, Amsterdam, The Netherlands.

Contributorship Statement

TAS: Study design, data collection, performed analyses

SPV Performed analyses, wrote manuscript

JFW study design, data collection, critically reviewing the manuscript

SO supervised data analyses, supervised writing, critically reading the manuscript

SAM study design, overall supervision, critically reading the manuscript.

Competing interests

None

Data sharing statement

No further data are available.

Reference List

- 1
2
3 1
4 2
5 3 [1] Trienekens SCM, Koedijk FDH, Van den Broek IVF, et al. Sexually transmitted
6
7 4 infections, including HIV, in the Netherlands in 2011. National Institute for
8
9 5 Public Health and the Environment, Bilthoven, The Netherlands; 2012. Report
10
11 6 No.: 201051001.
12
13
14 7 [2] Land JA, van Bergen JE, Morre SA, et al. Epidemiology of Chlamydia
15
16 8 trachomatis infection in women and the cost-effectiveness of screening. Hum
17
18 9 Reprod Update 2010 Mar;16(2):189-204.
19
20
21
22 10 [3] Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhoea and prevalence
23
24 11 of abnormal adnexal findings among women recently exposed to gonorrhoea.
25
26 12 JAMA 1983 Dec 16;250(23):3205-9.
27
28
29
30 13 [4] Goessens WH, Mouton JW, van der Meijden WI, et al. Comparison of three
31
32 14 commercially available amplification assays, AMP CT, LCx, and COBAS
33
34 15 AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin
35
36 16 Microbiol 1997 Oct;35(10):2628-33.
37
38
39
40 17 [5] Quint KD, van Doorn LJ, Kleter B, et al. A highly sensitive, multiplex broad-
41
42 18 spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for
43
44 19 rapid detection and identification of Chlamydia trachomatis serovars. J Mol
45
46 20 Diagn 2007 Nov;9(5):631-8.
47
48
49
50 21 [6] Hjelmevoll SO, Olsen ME, Sollid JU, et al. Clinical validation of a real-time
51
52 22 polymerase chain reaction detection of Neisseria gonorrhoeae porA pseudogene
53
54 23 versus culture techniques. Sex Transm Dis 2008 May;35(5):517-20.
55
56
57
58
59
60

- 1
2
3 1 [7] Morre SA, Meijer CJ, Munk C, et al. Pooling of urine specimens for detection of
4 asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence
5 2
6 asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence
7 3
8 population: cost-saving strategy for epidemiological studies and screening
9 4
10 programs. J Clin Microbiol 2000 Apr;38(4):1679-80.
11
12 [8] Spiegelman D, Schneeweiss S, McDermott A. Measurement error correction for
13 5
14 logistic regression models with an "alloyed gold standard". Am J Epidemiol 1997
15 6
16 Jan 15;145(2):184-96.
17 7
18 [9] Wilson EB. Probable inference, the law of succession, and statistical inference.
19 8
20 J Am Stat Assoc 1927;22:209-12.
21 9
22 [10] Jalal H, Al-Suwaine A, Stephen H, et al. Comparative performance of the Roche
23 10
24 COBAS Amplicor assay and an in-house real-time PCR assay for diagnosis of
25 11
26 Chlamydia trachomatis infection. J Med Microbiol 2007 Mar;56(Pt 3):320-2.
27 12
28 [11] Cheng A, Qian Q, Kirby JE. Evaluation of the Abbott RealTime CT/NG assay in
29 13
30 comparison to the Roche Cobas Amplicor CT/NG assay. J Clin Microbiol 2011
31 14
32 Apr;49(4):1294-300.
33 15
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **1 Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in an STI**
8 **2 population; performances of Presto CT-NG assay, Lightmix Kit 480 HT CT/NG,**
9 **3 and COBAS Amplicor with urine specimens and urethral/cervicovaginal**
10 **4 samples**
11
12
13
14
15

16 T.A. Schuurs^{1#}, S.P. Verweij^{2#}, J.F.L. Weel¹, S. Ouburg², S.A. Morré^{2,3+}
17
18
19

20 ¹Izore, Centre for Infectious Diseases Friesland, Leeuwarden, The Netherlands
21

22 ²Laboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU
23 University Medical Center, Amsterdam, The Netherlands
24

25 ³Institute of Public Health Genomics, Department of Genetics and Cell Biology, Research Institute
26 GROW, Faculty of Health, Medicine & Life Sciences, University of Maastricht, Maastricht, The
27 Netherlands
28
29
30

31 ⁺Address of correspondence: VU University Medical Center, Department of Medical
32 Microbiology and Infection Control, Laboratory of Immunogenetics, Location: MF
33 B330, To: S.A. Morré, Head Lol, De Boelelaan 1117, 1081 HV, Amsterdam, The
34 Netherlands
35
36
37
38

39 E-mail: samorretravel@yahoo.co.uk, Phone: +31-20-44-49375, Fax: +31-20-44-
40 48418
41
42

43 [#]These authors contributed equally to the manuscript
44
45
46

47 Abstract no. of words: 218 (max. 300)
48

49 Body text no. of words: 977 (max. 1000)
50

51 References: 11
52

53 Tables/figures: 2
54
55

1
2
3
4
5
6
7 **Article summary**
8

9
10
11 **Article focus**

- 12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- To evaluate performances of three commercially available nucleic acid amplification tests (NAAT) in the detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*: Presto [CT-NG assay](#), Lightmix Kit 480 HT CT/NG, and COBAS Amplicor.

9 **Key messages**

- Prevalence of *C. trachomatis* and *N. gonorrhoeae* is stable or slightly increasing in the Netherlands. Well functioning diagnostic tools are essential within the healthcare.
- All three NAATs evaluated in this study are highly sensitive and specific for detection of *C. trachomatis*, with best performance for [the Presto CT-NG assay](#).

17 **Strengths and limitations**

- Although our sample size was quite large, our study had a limited number of *N. gonorrhoeae* positive samples, so no sensitivities, specificities, positive predictive values and negative predicting values were calculated.

1
2
3
4
5
6
7 **Abstract**

8
9
10
11 **Objectives**

12 This study assessed the performances of Presto CT/NG assay, Lightmix Kit 480 HT
13 CT/NG, and the COBAS Amplicor for *Chlamydia trachomatis* and *Neisseria*
14 *gonorrhoeae* detection.
15
16
17

18
19
20 **Design**

21
22 It is a ~~prospective~~ cross-sectional study design.
23
24

25
26 **Setting**

27
28 IZORE, Centre for Diagnosing Infectious Diseases in Friesland, the Netherlands, tested
29 samples sent from regional STI outpatient clinics and regional hospitals from the
30 province Friesland, the Netherlands.
31
32
33
34

35
36 **Participants**

37 Samples were collected from 292 men and 835 women. These samples included 560
38 urine samples and 567 urethral/cervicovaginal samples.
39
40
41
42

43
44 **Primary and secondary outcome measures**

45 Primary outcome measure is *C. trachomatis* infection. No secondary outcome
46 measures are available.
47
48
49
50

51 **Results**
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 1 The sensitivity, specificity, positive predicative value (PPV), and negative predictive
8 2 value (NPV) for *C. trachomatis* detection in urine samples using Presto were 100,0%,
9 3 99,8%, 98,1%, 100,0%, respectively; for Lightmix Kit 480 HT CT/NG: 94,2%, 99,8%,
10 4 96,1%, 99,4%, respectively; for COBAS Amplicor: 92,3%, 99,6%, 96,0%, 99,2%,
11 5 respectively. The sensitivity, specificity, PPV, and NPV for *C. trachomatis* detection in
12 6 urethral/cervicovaginal swabs using Presto and COBAS Amplicor were 100,0%,
13 7 99,8%, 97,7%, 100,0%, respectively; for Lightmix Kit 480 HT CT/NG: 100,0%, 99,6%,
14 8 97,7%, 100,0%, respectively. Calculations for *N. gonorrhoeae* could not be made due
15 9 to a low prevalence.
16
17
18
19
20
21
22
23
24
25

26 11 **Conclusions**

27
28 12 All three assays had a high sensitivity, specificity, PPV, and NPV for *C. trachomatis*,
29
30 13 with best performance for the Presto CT/NG assay.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Introduction

Urogenital *Chlamydia trachomatis* and *Neisseria gonorrhoeae* are the most prevalent bacterial sexually transmitted infections (STI) in the Netherlands [1]. In women, both infections are associated with severe sequelae including pelvic inflammatory disease, tubal scarring, and tubal infertility [2;3]. In Western society, highly sensitive and specific DNA or RNA amplification tests to detect *C. trachomatis* and *N. gonorrhoeae* are commercially available, and have increased detection rates as compared to conventional techniques including culture [4-6]. A variety of clinical specimens, *i.e.* urine specimens and cervicovaginal, anorectal, or oropharyngeal swabs, can be used for STI detection, and cost-saving test strategies have been described [2;7]. Until recently, COBAS Amplicor (Roche, CA, USA) was the most widely used system for *C. trachomatis* and *N. gonorrhoeae* detection in the Netherlands. Newly developed dual detection systems for *C. trachomatis* and *N. gonorrhoeae* are implemented in Europe in the last two years including the Presto CT-NG assay (Goffin Molecular Technologies, Houten, The Netherlands) and the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany).

The aim of this prospective study was to compare the performances of the Presto CT-NG assay, the Lightmix Kit 480 HT CT/NG, and COBAS Amplicor in urine specimens and urethral/cervicovaginal samples for the detection of *C. trachomatis* and *N. gonorrhoeae* in patients visiting general practitioners, gynaecologists and dermato-venereologists for complaints most commonly generated by an STI.

1 **Material and Methods**

3 **Clinical specimens**

4 Urine specimens (n = 560, 238 men and 322 women) and urethral/cervicovaginal
5 swabs (n = 567, 54 men and 513 women) were obtained from 292 men and 835
6 women. Urethral samples were obtained from men only. Samples were sent to Izore,
7 Centre for Diagnosing Infectious Diseases in Friesland, the Netherlands, for routine
8 STI testing by regional hospitals and general practitioners. Samples were obtained in
9 the period from March - May 2010.

11 **DNA isolation**

12 DNA was isolated with MP96 (Roche) according to manufacturer's protocol. DNA
13 extraction from the urine samples and swabs for the COBAS Amplicor was performed
14 on the COBAS platform.

16 ***C. trachomatis* and *N. gonorrhoeae* testing**

17 *C. trachomatis* and *N. gonorrhoeae* detection was performed with the Presto CT-NG
18 assay (Goffin Molecular Technologies, Houten, The Netherlands), the Lightmix Kit
19 480 HT CT/NG (TIB MOLBIOL, Berlin, Germany), and COBAS Amplicor (Roche, CA,
20 USA). All tests were performed according to the protocols provided by the respective
21 manufacturers. Due to cross-reactivity with other *Neisseria spp.*, COBAS Amplicor-
22 positive-results were confirmed with *opa* PCR. Two qualified technicians performed
23 the tests and were blinded for the results.

1 Discrepancy analysis and statistical analysis

2 Samples identified as *C. trachomatis* positive or *C. trachomatis* negative with Presto
3 [CT-NG assay](#), [Lightmix Kit 480 HT CT/NG/TIB-MOLBIOL](#), and COBAS AmpliCor were
4 defined as true positives and true negatives, respectively using an alloyed gold
5 standard: If two out of three tests were positive, the sample was considered positive.
6 If only one test was positive, the sample was considered negative. The same
7 algorithm was used for *N. gonorrhoeae*.
8 To calculate the sensitivity, specificity, positive predictive value (PPV), and the
9 negative predictive value (NPV), we used the alloyed gold standard as reference [8].
10 95% Wilson Binomial Confidence Intervals were calculated for the sensitivities,
11 specificities, PPVs, and NPVs [9].

1 Results

2
3 The overall prevalence for *C. trachomatis* and *N. gonorrhoeae* in this study was 8.1-
4 8.5% and 0.8-0.9% respectively. Since the number of *N. gonorrhoeae* positive
5 samples was very limited, we could not reliably calculate sensitivity, specificity, PPV,
6 and NPV.

7
8 Using the Presto [CT-NG](#) assay *C. trachomatis* DNA was detected in 53 out of 560
9 urine specimens and in 43 out of 567 urethral/cervicovaginal specimens, while the
10 Lightmix Kit 480 HT CT/NG and COBAS Amplicor resulted in 51 and 40, and 50 and
11 43 *C. trachomatis* positives, respectively. The sensitivity, specificity, PPV and NPV
12 for *C. trachomatis* are summarized in Table 1.

13
14 For *N. gonorrhoeae*, Presto [CT-NG assay](#) detected 3 out of 560 urine specimens and
15 7 out of 567 urethral/cervicovaginal specimens. The Lightmix Kit 480 HT CT/NG and
16 COBAS Amplicor (followed by opaA confirmation PCR on *N. gonorrhoeae* positives)
17 detected 3 and 7, and 1 and 8 respectively.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1 | **Table 1. Sensitivity, specificity, PPV and NPV for the three assays for *C. trachomatis* detection.**

Formatted: Font: Italic

Urine <i>C. trachomatis</i>								
	Sensitivity	95% CI	Specificity	95% CI	PPV	95% CI	NPV	95% CI
Presto CT ₂ -NG assay	100,0	0,9932 - 1,000	99,8	0,9896 - 0,9996	98,1	0,9660 - 0,9895	100,0	0,9932 - 1,000
Lightmix Kit 480 HT CT/NG	94,2	0,9195 - 0,9585	99,8	0,9896 - 0,9996	96,1	0,9416 - 0,9741	99,4	0,9834 - 0,9978
Cobas Amplicor	92,3	0,8980 - 0,9423	99,6	0,9864 - 0,9988	96,0	0,9404 - 0,9733	99,2	0,9806 - 0,9967

Urethral/cervicovaginal <i>C. trachomatis</i>								
	Sensitivity	95% CI	Specificity	95% CI	PPV	95% CI	NPV	95% CI
Presto CT ₂ -NG assay	100,0	0,9933 - 1,000	99,8	0,9897 - 0,9996	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000
Lightmix Kit 480 HT CT/NG	100,0	0,9933 - 1,000	99,6	0,9865 - 0,9988	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000
Cobas Amplicor	100,0	0,9933 - 1,000	99,8	0,9897 - 0,9996	97,7	0,9611 - 0,9865	100,0	0,9933 - 1,000

Discussion

In the Netherlands, the prevalence of STI is stable or slightly increasing [1]. Besides education also accurate diagnostics is essential for prevention of further spreading of STI in the healthy population. Therefore diagnostic tests, detecting STI's, should display maximum sensitivity whereas false-positives have to be precluded at any time.

We compared the performance of the Presto CT-NG assay (Goffin Molecular Technologies), the Lightmix Kit 480 HT CT/NG (TIB MOLBIOL), and the Cobas Amplicor (Roche) to an alloyed gold standard, defined as a positive result in at least two out of three tests. The used samples were urine and urogenital swabs. The results show high specificity, sensitivity, PPV, and NPV for all tests, with the Presto CT-NG assay as best overall performance *for C. trachomatis*.

Formatted: Font: Italic

Due to the low prevalence of *N. gonorrhoeae*, we were not able to calculate specificity, sensitivity, PPV, and NPV. Presto CT-NG assay and Lightmix Kit 480 HT CT/NG detected *N. gonorrhoeae* equally, but for a definitive validation more samples are needed. The overall prevalence of *N. gonorrhoeae* in this study population was 0.8-0.9%, which is in concordance with a recent report of the National Institute for Public Health and the Environment stating that Friesland province has an *N. gonorrhoeae* prevalence of 1-2% [1]. The prevalence of *C. trachomatis* in this study population is slightly lower than the reported annual prevalence: 8.1-8.5% vs. 12-14% [1]. This observed difference may be explained by the fact that the National Institute for Public Health and the Environment includes data from all STI outpatient clinics in the Netherlands, whereas this study uses samples from a single region.

1
2
3
4
5
6
7 1
8
9 2 Performance of the COBAS Amplicor regarding *C. trachomatis* detection in this study
10
11 3 was comparable to its performance in other studies [10;11]. In these other studies,
12
13 4 similar high sensitivities, specificities, PPVs, and NPVs were achieved, as we
14 5 ~~foundde~~ in this study. ~~Due to too small number specificity, sensitivity, PPV and NPV~~
15
16 6 ~~could not be calculated for *N. gonorrhoeae*.~~
17
18 7
19
20 8 To conclude, we find high specificity, sensitivity, PPV, and NPV for all tests for *C.*
21
22 9 *trachomatis*, with the Presto CT-~~NG~~ assay having the best overall performance.
23
24 10

1 Acknowledgements

2
3 We would like to acknowledge Renske Minnema and Griet Verbeek (Izore, Centre for
4 Infectious Diseases Friesland, Leeuwarden, The Netherlands) for the technical
5 support. Prof.dr. S.A. Morré, employed by the VU University medical center has been
6 involved in the technical development of the Presto [CT-NG assay-test](#) (Goffin
7 Molecular Technologies, Houten, The Netherlands) via Microbiome Ltd., a spin-in
8 company of the VU University [medical center](#), Amsterdam, The Netherlands.


Reference List

- [1] Trienekens SCM, Koedijk FDH, Van den Broek IVF, Vriend HJ, Op de Coul ELM, Van Veen MG, et al. Sexually transmitted infections, including HIV, in the Netherlands in 2011. National Institute for Public Health and the Environment, Bilthoven, The Netherlands; 2012. Report No.: 201051001.
- [2] Land JA, van Bergen JE, Morre SA, Postma MJ. Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Hum Reprod Update 2010 Mar;16(2):189-204.
- [3] Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhoea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhoea. JAMA 1983 Dec 16;250(23):3205-9.
- [4] Goessens WH, Mouton JW, van der Meijden WI, Deelen S, van Rijsoort-Vos TH, Lemmens-den TN, et al. Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol 1997 Oct;35(10):2628-33.
- [5] Quint KD, van Doorn LJ, Kleter B, de Koning MN, van den Munckhof HA, Morré SA, et al. A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identification of Chlamydia trachomatis serovars. J Mol Diagn 2007 Nov;9(5):631-8.

- 1
2
3
4
5
6
7 [6] Hjelmevoll SO, Olsen ME, Sollid JU, Haaheim H, Melby KK, Moi H, et al.
8 Clinical validation of a real-time polymerase chain reaction detection of
9 Neisseria gonorrhoeae porA pseudogene versus culture techniques. Sex Transm
10 Dis 2008 May;35(5):517-20.
11
12
13
14
15 [7] Morre SA, Meijer CJ, Munk C, Kruger-Kjaer S, Winther JF, Jorgensens HO, et
16 al. Pooling of urine specimens for detection of asymptomatic Chlamydia
17 trachomatis infections by PCR in a low-prevalence population: cost-saving
18 strategy for epidemiological studies and screening programs. J Clin Microbiol
19 2000 Apr;38(4):1679-80.
20
21
22
23
24
25 [8] Spiegelman D, Schneeweiss S, McDermott A. Measurement error correction for
26 logistic regression models with an "alloyed gold standard". Am J Epidemiol 1997
27 Jan 15;145(2):184-96.
28
29
30
31
32 [9] Wilson EB. Probable inference, the law of succession, and statistical inference.
33 J Am Stat Assoc 1927;22:209-12.
34
35
36
37 [10] Jalal H, Al-Suwaine A, Stephen H, Carne C, Sonnex C. Comparative
38 performance of the Roche COBAS Amplicor assay and an in-house real-time
39 PCR assay for diagnosis of Chlamydia trachomatis infection. J Med Microbiol
40 2007 Mar;56(Pt 3):320-2.
41
42
43
44
45 [11] Cheng A, Qian Q, Kirby JE. Evaluation of the Abbott RealTime CT/NG assay in
46 comparison to the Roche Cobas Amplicor CT/NG assay. J Clin Microbiol 2011
47 Apr;49(4):1294-300.
48
49
50
51
52
53
54
55
56
57
58
59
60

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	5
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	65
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	65
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	65
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	54
<i>Test methods</i>	7	The reference standard and its rationale.	76
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	5, 66, 7
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	5, 6, 7
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	65
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	65
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	76
	13	Methods for calculating test reproducibility, if done.	n/a
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	n/a
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	65, 87
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	87
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	n/a
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	n/a
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	n/a
	20	Any adverse events from performing the index tests or the reference standard.	n/a
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	98
	22	How indeterminate results, missing data and outliers of the index tests were handled.	n/a
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	n/a
	24	Estimates of test reproducibility, if done.	n/a
DISCUSSION	25	Discuss the clinical applicability of the study findings.	109



Flow chart of the study
101x90mm (300 x 300 DPI)

only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60